Key result
Newly identified metastatic prostate cancer presents atypically with recurrent ischemic and hemorrhagic strokes.
Why the study?
Most stroke trials have excluded patients with malignancy, leaving limited evidence to guide management decisions in cancer patients who face an increased risk of stroke.
Case Report (n=1)
Highlights the complex management of recurrent strokes in patients with metastatic prostate cancer, a population often excluded from major stroke trials.
Answers are grounded in this paper and cite their sources.
May prompt malignancy evaluation in recurrent mixed strokes; leaves open optimal management in metastatic prostate cancer.
Cancer and stroke comprise two of the most common causes of death worldwide. Despite a significantly increased risk of stroke among patients with cancer, most stroke trials have excluded patients with malignancy. There is thus limited evidence to help guide management decisions in this complex population. We present the case of a 78-year-old man with recurrent strokes - both ischemic and hemorrhagic - in the setting of newly-identified metastatic prostate cancer. An atypical cause of cancer-associated stroke is reviewed and the management is discussed.
No takes yet. Share an insight, caveat, or question.
Zuflacht et al. (2023) conducted a case report in Recurrent strokes and metastatic prostate cancer (n=1). A 78-year-old man presented with recurrent ischemic and hemorrhagic strokes in the setting of newly-identified metastatic prostate cancer, highlighting an atypical cause of cancer-associated stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: